Cabozantinib is also being studied in a variety of other cancers, including heavily pretreated, refractory renal cell carcinoma and medullary thyroid cancer.
Exelixis sponsored both trials. Dr. Lee reported no conflicts. Dr. Smith and several of his coauthors reported a consultant/advisory role with and research funding from Exelixis. Dr. Fizazi reported a consultant/advisory role with OncoGenex and Exelixis.